FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS

Clinical evidence from FLEX


Neoadjuvant publications

Evidence / Neoadjuvant / FLEX

Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX

Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce Oโ€™Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrintยฎ Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: โ€ข Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More

Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicineโ€”Biology Is Still King

Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce Oโ€™Shaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicineโ€”Biology Is Still King Abtract: Clinical Read More

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposiumยฎ Authors: Joyce Oโ€™Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigatorsโ€™ Group Title: MammaPrintยฎ and BluePrintยฎ Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More